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Non-small-cell lung carcinoma (NSCLC) is the major type of lung cancer, which is among
the leading causes of cancer-related deaths worldwide. LIMD1 was previously identiﬁed
as a tumor suppressor in lung cancer, but their detailed interaction in this setting remains
unclear. In this study, we have carried out multiple genome-wide bioinformatic analyses
for a comprehensive understanding of LIMD1 in NSCLC, using various online algorithm
platforms that have been built for mega databases derived from both clinical and cell line
samples. Our results indicate that LIMD1 expression level is signiﬁcantly downregulated at
both mRNA and protein levels in both lung adenocarcinoma (LUAD) and lung squamous
cell carcinoma (LUSC), with a considerable contribution from its promoter methylation
rather than its gene mutations. The Limd1 gene undergoes mutation only at a low rate in
NSCLC (0.712%). We have further identiﬁed LIMD1-associated molecular signatures in
NSCLC, including its natural antisense long non-coding RNA LIMD1-AS1 and a pool of
membrane trafﬁcking regulators. We have also identiﬁed a subgroup of tumor-inﬁltrating
lymphocytes, especially neutrophils, whose tumor inﬁltration levels signiﬁcantly correlate
with LIMD1 level in both LUAD and LUSC. However, a signiﬁcant correlation of LIMD1 with
a subset of immune regulatory molecules, such as IL6R and TAP1, was only found in
LUAD. Regarding the clinical outcomes, LIMD1 expression level only signiﬁcantly
correlates with the survival of LUAD (p<0.01) but not with that of LUSC (p>0.1)
patients. These ﬁndings indicate that LIMD1 plays a survival role in LUAD patients at
least by acting as an immune regulatory protein. To further understand the mechanisms
underlying the tumor-suppressing function of LIMD1 in NSCLC, we show that LIMD1
downregulation remarkably correlates with the deregulation of multiple pathways that play
decisive roles in the oncogenesis of NSCLC, especially those mediated by EGFR, KRAS,
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PIK3CA, Keap1, and p63, in both LUAD and LUSC, and those mediated by p53 and
CDKN2A only in LUAD. This study has disclosed that LIMD1 can serve as a survival
prognostic marker for LUAD patients and provides mechanistic insights into the interaction
of LIMD1 with NSCLC, which provide valuable information for clinical applications.
Keywords: LIMD1, lung cancer, algorithm analysis, LUAD, LUSC

INTRODUCTION

METHODS

Lung cancer is among the leading causes of cancer-related deaths
in the world. There are nearly 230 thousand of new lung cancer
patients and more than 135 thousand of deaths in 2020 in the
USA (American Cancer Society). The 5-year relative survival rate
of lung cancer from 1995 to 2001 was 15.7%. Non-small-cell lung
carcinoma (NSCLC) is the major histological type of lung cancer
that contributes to approximately 85% of all lung cancers. Like
small-cell lung carcinoma (SCLC), NSCLC is originated from
epithelial cells, and includes two main subtypes: lung
adenocarcinoma (LUAD) and lung squamous cell carcinoma
(LUSC). NSCLC patients are relatively insensitive to
chemotherapy and radiation therapy compared with SCLC
patients, and innovative therapeutic strategies are desired.
The adaptor protein LIMD1 is a member of the ZYXIN family
(1). In humans, the Limd1 gene is located at chromosome 3p21.3
(2), a region that undergoes frequent loss of heterozygosity in
many solid tumors including both small and non-small cell lung
cancers (2–7). LIMD1 possesses either pro-oncogenic or antioncogenic properties in different contexts. It was originally
identiﬁed as a tumor suppressor in lung cancer (2, 8), and also
plays a tumor-suppressing role in gastric cancer (9). It has been
shown to regulate metastasis in breast, lung, and gastric cancers
(2, 9, 10). In contrast, our recent studies have shown that LIMD1
plays a pro-oncogenic role in hematological malignancies in
association with the oncogenic transcription factor interferon
regulatory factor 4 (IRF4) (11, 12).
A few mechanisms underneath LIMD1-mediated suppressing
functions in cancer have been disclosed. LIMD1 can interact with
context-speciﬁc factors to execute its functions. For example,
LIMD1 interacts with the tumor suppressor Rb to inhibit E2Fmediated gene transcription in the nucleus in AML (2), with
VHL, PHD, and RHOBTB3 to repress HIF1a activity by
promoting its ubiquitination-mediated degradation in response
to cancer hypoxia (5, 13), and with LATS and WW45 to
negatively regulate the anti-oncogenic Hippo signaling (14).
Thus, its interacting partners play determinant roles in its
functional consequences.
To gain a comprehensive understanding of the association of
LIMD1 with the development of NSCLC, in this study, we have
employed various online algorithms to conduct secondary
analyses of available datasets. We show that LIMD1 expression
is signiﬁcantly downregulated in NSCLC, and have identiﬁed
LIMD1-associated tumor-inﬁltrating immune cells (TILs), and
molecular and immune signatures in this setting. More
importantly, we found that LIMD1 signiﬁcantly correlates with
the survival of LUAD but not that of LUSC patients.

We employed different online algorithms for metadata analysis,
including Oncomine, Genotype-Tissue Expression (GTEx),
Gene Expression Atlas, ProteinAtlas, ProteomicsDB, Tumor
Immune Estimation Resource (TIMER v2) (15, 16), Gene
Expression Proﬁling Interactive Analysis (GEPIA v2) (17),
Tumor-Immune System Interactions Database (TISIDB) (18),
UALCAN (19), COSMIC, Tumor Fusion Gene Data Portal
(TumorFusions) (20), FusionGDB (21), ChimerDB v4 that
integrates several different fusion portals such as STARFusion,
TCGA-FAWG, and FusionScan (22), cBioportal (23, 24),
DriverDBv3 (25), Kaplan Meier Plotter (KMPlot) (26),
muTarget (27), SMART (28), Lung cancer explorer (LCE), and
ENSEMBL, for mRNA and protein expression, correlation, gene
mutation, promoter methylation, fusion, tumor-immune
interaction, and survival analyses. All portals include the
Cancer Genome Atlas (TCGA) datasets, in addition to other
unique datasets obtained from patients and cell lines. BioGRID
(29, 30), GeneMANIA (31, 32), STRING, Uniprot, and KEGG,
and PhosphoSitePlus portals were applied for post-translational
modiﬁcations, signaling pathway, and protein-protein and
functional interaction analyses.
All analyses were carried out using the default settings of the
corresponding algorithms if not otherwise indicated, with the
detailed dataset information and guidelines available on each
algorithm portal. p<0.05 is considered statistically signiﬁcant
and >0.05 is non-signiﬁcant (n.s), and p<0.01 is considered
statistically very signiﬁcant.
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RESULTS
Tissue- and Cell-Speciﬁc Expression
of LIMD1
To understand the role of LIMD1, we ﬁrst evaluated its tissueand cell-speciﬁc expression patterns in humans, in GTEx, Gene
Expression Atlas, and ProteinAtlas portals, which include
datasets obtained from human protein atlas (HPA), functional
annotation of the mammalian genome (FANTOM v5), and
GTEx projects. The Limd1 gene produces four alternatively
spliced variants (Figure 1A). The ENSEMBL portal shows that
two of these four splice variants encode proteins, with the size of
676 aa for the dominant transcript ENST00000273317.4 and 620
aa for ENST00000440097.5. Analysis in the GTEx portal
indicates that three of the four splice variants are widely
expressed in various tissues and cell lines (Figure 1B), with the
highest levels in lung and Epstein-Barr virus (EBV)-transformed
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FIGURE 1 | Tissue- and cell-speciﬁc expression of LIMD1. (A) Four splicing variants of Limd1 primary transcript, two of which encode proteins (676 aa for the
dominant transcript ENST00000273317.4 and 620 aa for ENST00000440097.5). (B, C) Tissue-speciﬁc expression of Limd1 splicing variants and gene. (D) Cellspeciﬁc expression of Limd1 transcript. (E) Cell-speciﬁc expression of Limd1 transcript in the blood. (A–C) are the results from the GTEx portal, and (D, E) from the
ProteinAtlas portal. TPM, transcripts per million; NX, denoted normalized expression.
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lymphoblastic cell lines (LCLs) (Figures 1B, C). Analysis in
ProteomicsDB shows that the encoded LIMD1 protein displays a
tissue-speciﬁc differential expression pattern similar to that of
Limd1 transcription (data not shown). Consistent with these
results, our recent studies have shown that LIMD1 is induced by
NFkB and IRF4 downstream of the signaling pathway triggered
by the EBV principal oncoprotein LMP1 in EBV-transformed
LCLs, suggesting that LIMD1 could serve as an oncogenic
biomarker in association with NFkB and IRF4 in certain
hematological malignancies (11, 12).
Regarding cell-speciﬁc expression, analysis in the ProteinAtlas
portal shows that the transcript abundance of LIMD1 is mainly
enriched in the cells originated from lymphoid, brain, and lung
(Figure 1D). In the blood, LIMD1 is mainly expressed in
plasmacytoid dendritic cells, followed by B cells, basophils, and
monocytes (Figure 1E).

Most, if not all, neoplasms generated in response to
environmental carcinogens result from mutations that initiate
cancerogenesis. In general, a given cancer requires 2–8 mutations
to initiate (39). Mutation analysis of TCGA dataset in TIMER,
cBioportal, and DriverDBv3 portals shows that the Limd1 gene
undergoes low rates of mutation in NSCLC (4/485 in LUSC and
4/517 in LUAD), but undergoes higher rates in DLBC (2/37),
UCEC (16/531), and cholangiocarcinoma (CHOL, 1/36) (Figure
3A). Regarding lung cancer, in agreement with previous reports
(4, 40), TCGA lung cancer cohort comprises high frequencies of
Limd1 arm-level deletion correlating with somatic copy number
alteration (sCNA), with LUSC (>75%) being higher than LUAD
(~50%) (Figure 3B). Further analysis in COSMIC portal shows
that Limd1 cDNA somatic mutations (substitutions, deletions,
and insertions) were detected in 33 out of 226 lung cancer
samples (14.6%), with most being missense substitution
(57.58%) (Figure 3C). cBioportal analysis shows that Limd1
has a rate of 0.712% of mutations in NSCLC patients (43/6040)
(not shown). ChimerDB and TumorFusions portals indicate
that, among these detected Limd1 mutation types, Limd1-Lars2
gene fusion occurs in both LUAD and LUAC tumors and also in
STAD, with Tier 1 in-frame fusion in LUAD and Tier 2 out-offrame fusion in LUSC (Supplementary Figure 3). cBioportal
analysis shows that Dhx30-Limd1 fusion occurs in PRAD,
Sacm1l-Limd1 fusion occurs in BRCA, and Vgll4-Limd1 fusion
occurs in BLCA, with Vgll4-Limd1 fusion resulting in a
remarkable increase of LIMD1 expression (Figure 3D).
FusionGDB indicates that two other fusion genes, Limd1-Dsp
and Plec-Limd1, exist in diseases other than cancers. Consistent
results from different portals, including cBioportal and TIMER2,
indicate that the overall Limd1 mutation in different cancers has
no signiﬁcant effects on its expression (Figures 3D, E), although
the analysis was not performed for some types of cancer in that
their sample sizes with Limd1 mutation are not powerful enough.
Together, these ﬁndings support the claim that the
deregulation of LIMD1 expression in different cancers mainly
results from epigenetic reprogramming rather than its mutation,
with its downregulation in NSCLC being partially attributed to
promoter methylation and arm-level deletion. In addition to
these epigenetic mechanisms, miRNAs likely regulate LIMD1
expression in different cancer contexts, with miR-127-5p, miR147a, and miR-130b-3p that potentially target LIMD1 in LUAD,
as analyzed in DriverDBv3 (Supplementary Table 1).

LIMD1 Is Downregulated in NSCLC
We next analyzed LIMD1 mRNA abundance in different human
cancers, using Oncomine, TIMER2.0, GEPIA2, UALCAN, and
DriverDBv3. Results from these different portals show that
LIMD1 transcript is signiﬁcantly downregulated in NSCLC
(LUAD and LUSC), uterine corpus endometrial carcinoma
(UCEC), and uterine carcinosarcoma (UCS), and upregulated in
lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), breast
cancer (BRCA), glioblastoma multiforme (GBM), acute myeloid
leukemia (LAML), and brain lower-grade glioma (LGG) (Figures
2A-C; Figure 5C; Supplementary Figures 1, 2). In agreement with
these results, LIMD1 deregulation was previously found in lung
cancer, non-Hodgkin lymphomas, gastric and colorectal
carcinomas, and breast cancer (8, 33–35). The portal Oncomine
comprises different datasets with lung cancer clinical or cell line
samples, and only those within our statistical power and appropriate
controls were selected for analysis (Figure 2). Consistently, LIMD1
protein and S233 phosphorylation levels are downregulated in
LUAD and LUSC, as analyzed in UALCAN (Figures 2D, E). In
fact, S233 phosphorylation of LIMD1 has been identiﬁed by high
throughput proﬁling assays in many other cancers, including breast
and ovarian cancers and pancreatic ductal adenocarcinoma, with or
without stresses (36–38).
Promoter methylation analysis of TCGA lung cancer dataset
in SMART portal indicates that the Limd1 gene promoter is
highly methylated in a region spanning nucleotides 45559963 to
45678725 in both LUAD and LUSC, exempliﬁed by the probe
cg15765353 that covers the two nucleotides 45559963-4 (p=4e-7
for LUAD and p=9.1e-11 for LUSC) (Figures 2F, G). Pearson
and Spearman correlation analyses in cBioportal, which includes
TCGA and other lung cancer datasets, show that the Limd1 gene
promoter methylation signiﬁcantly correlates with its
downregulation in both LUAD and LUSC cancers, with a
greater correlation coefﬁcient in LUAD (Figures 2H, I).
Similar results were obtained in DriverDBv3 for TCGA lung
cancer dataset (R=-0.361; p=3.16e-17 for LUAD vs R=-0.246;
p=2.92e-8 for LUSC). These ﬁndings indicate that Limd1 gene
promoter methylation makes a signiﬁcant contribution to the
downregulation of LIMD1 expression in NSCLC.

Frontiers in Oncology | www.frontiersin.org

LIMD1 Differential Expression and
Correlation Patterns in NSCLC
We further analyzed TCGA lung cancer 2 dataset, which includes
1,537 lung cancer samples (420 blood and 1,117 tissue samples,
comprising 370 LUAD, 357 LUSC, and 810 unclassiﬁed), in the
Oncomine portal. Results show that LIMD1 downregulation
occurs at the early stage of cancer development in both LUAD
and LUSC, and there are no signiﬁcant differences between every
two stages (Figures 4A, B). However, smoke status, ages, gender,
and race have no signiﬁcant correlation with LIMD1 deregulation
in NSCLC (Figures 4A, F; data not shown for gender and race).
Similar results were obtained from other lung cancer datasets in
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FIGURE 2 | LIMD1 is downregulated in NSCLC. (A) Deregulation of LIMD1 at the transcriptional level in various cancers (*: p < 0.05; **: p<0.01; ***: p<0.001). Blue:
Normal tissues; Red: Tumor tissues. Pink: Tumor tissues without normal tissue controls; Purple: Metastasis tumor tissues. ACC: Adrenocortical carcinoma; BLCA:
Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL:
Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC:
Head and Neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML:
Acute myeloid leukemia; LGG: Brain lower-grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell
carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma;
PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT:
Testicular germ cell tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine corpus endometrial carcinoma; UCS: Uterine carcinosarcoma; UVM: Uveal
melanoma. (B, C) LIMD1 transcription is downregulated in LUAD and LUSC, respectively. (D, E) LIMD1 protein level and S233 phosphorylation are downregulated in
LUAD. (F, G) LIMD1 promoter is signiﬁcantly methylated in both LUAD and LUSC. (H, I) LIMD1 gene transcription negatively correlates with its promoter methylation
in LUAD and LUSC, respectively. (A) is the results from the TIMER2 portal, (B, G) from UALCAN, and (H, I) from cBioportal.
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FIGURE 3 | Proﬁle of Limd1 gene mutation in cancers. (A) Frequencies of Limd1 gene mutation in various cancers. (B) Frequencies of Limd1 somatic copy number
alteration (sCNA). (C) Frequencies of Limd1 somatic mutations (substitutions, deletions, and insertions) in NSCLC. (D) Effects of LIMD1 mutation on its expression in
various cancers. (E) Representative results from LUAD and UCEC show that LIMD1 mutation has no signiﬁcant effects on its expression. (A, B, E) are the results
from TIMER2, (C) from COSMIC, and (D) from cBioportal. FC, Fold change.

In addition to these frequently mutated genes, we further
analyzed whether mutations of any other genes may affect
LIMD1 expression in NSCLC in the muTarget portal. Results
show that, in a panel of mutated genes (Supplementary Table 2),
OR4C15, RALGAPA1, SPAM1, TRPV3, and WDR17 genes in
LUAD, and AMPD3 in LUSC are at the top rank whose mutation
signiﬁcantly results in LIMD1 downregulation (p<0.01; fold
change>1.44) (Supplementary Figure 5).
We next performed genome-wide association studies
(GWAS) to proﬁle LIMD1-associated molecular signatures in
lung cancer, in Oncomine, GEPIA2, and UALCAN portals, using
the Pearson correlation test. These analyses identiﬁed a panel of

Oncomine and also from the analysis in the UALCAN portal
(not shown).
The genes encoding p53, KRAS, EGFR, ALK, PTEN, and PI3K
are frequently mutated in lung cancers (Supplementary Figure 4).
We thus assessed whether mutation of these key genes correlates
with LIMD1 expression levels in the TIMER2 portal. Results show
that mutation of p53 (p=8.6e-8; log2(FC)=-0.13) and PTEN
(p=0.0098; log2(FC)=-0.258) genes correlates with LIMD1
downregulation in LUAD but not LUSC patients (Figure 4G;
data for LUSC not shown). Similar results were obtained for p53
mutation in the UALCAN portal (p=7.535e-08 for LUAD and
p=0.962 for LUSC).

Frontiers in Oncology | www.frontiersin.org
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analysis in GEPIA2 and/or TIMER2 portals, and representative
results for UNC13B, RBSN, and LIMD1-AS1 are shown in
Figure 5B.
LIMD1-AS1 perfectly correlates with LIMD1 not only in lung
cancer, but also in all other types of cancers in the TCGA dataset
(Figure 5C). In support of this observation, LIMD1-AS1 was
recently shown to stabilize LIMD1 mRNA in a hnRNP-Umediated manner in lung cancer (41). RBSN belongs to the
FYVE zinc ﬁnger family, members of which bind to the
membrane lipid phosphatidylinositol-3-phosphate (PtdIns(3)P)
with high speciﬁcity. SACM1L is a phosphoinositide phosphatase
that catalyzes the hydrolysis of PtdIns(4)P. UNC13B plays a role in
vesicle maturation during exocytosis, and ATP11A is the catalytic
component of a P4-ATPase ﬂippase complex that catalyzes the
hydrolysis of ATP coupled to the transport of amino-phospholipids
from the outer to the inner leaﬂet of various membranes. These
intriguing ﬁndings imply that LIMD1 has an intimate association
with membrane trafﬁcking. In support of this role, the LIMD1
proteins have been reported to play a role in actin ﬁlament assembly
and cytoskeletal organization (1, 42) we have collected a pool of
preliminary data showing that LIMD1 is important for
autophagosome biogenesis induced by oxidative stress in cancer
cells (to be published).
Additionally, we identiﬁed LUAD- and LUSC-speciﬁc genes
that correlate with LIMD1 at the transcriptional level in GEPIA2
and UALCAN portals (Supplementary Table 3).

G

LIMD1 Expression Level Correlates With
the Frequencies of Distinct TumorInﬁltrating Lymphocytes in LUAD
and LUSC
Tumor-inﬁltrating lymphocytes (TILs), an important
component of the tumor microenvironment (TME), can
recognize and kill cancer cells, and are an ideal candidate for
cellular immunotherapy for various cancers (43–46). Especially
in NSCLC, where the efﬁcacy of immune checkpoint inhibitors
(ICIs) is a concern since only a limited percentage of NSCLC
patients have gotten promising prognoses (47, 48). Thus, the
identiﬁcation of novel biomarkers associated with TILs is of great
importance in NSCLC clinical applications.
We, therefore, sought to assess the correlation of LIMD1
expression with different subtypes of TILs in NSCLC, including
CD4 T cells, CD8 T cells, B cells, NK cells, dendritic cells (DCs),
macrophages, myeloid-derived suppressor cells (MDSCs), mast
cells, neutrophil, eosinophils, cancer-associated ﬁbroblasts,
endothelial cells, common lymphoid and myeloid progenitors,
and hematopoietic stem cells, using Spearman correlation test in
TIMER2 portal. We set the cutoff values of the Spearman
coefﬁcient to R<-0.33 (negative correlation) or R>0.33 (positive
correlation), and p<0.05 was considered signiﬁcant. Within these
cutoff criteria, we found that LIMD1 expression levels positively
correlate with the inﬁltration of neutrophils, CD4+ T cells,
endothelial cells, and mast cells in both LUAD and LUSC
(Figure 6A). Of note, among all subtypes of TILs, neutrophils
are the majority in both LUAD and LUSC (the inﬁltration level is
peaked approximately at 100 in LUAD and LUSC) (Figure 6A).

FIGURE 4 | LIMD1 differential expression patterns in lung cancer stages and
its regulation by gene mutation. (A, B) LIMD1 is downregulated at the early
stages of NSCLC. (C, D) Clinical stages of lung cancer have no signiﬁcant
differences in LIMD1 expression. (E) Smoke status has no signiﬁcant effects
on LIMD1 expression. (F) Ages have no signiﬁcant effects on LIMD1
expression. (G) Effects of mutation of key lung cancer genes on LIMD1
expression in LUAD. (A, B) are the results from UALCAN portal, (C, F) from
Oncomine, and (G) from TIMER2.

common genes that correlate with LIMD1 (PCC>0.5) at the
mRNA level in both LUAD and LUSC, and representative results
from the GEPIA2 portal are shown in Figure 5A. Among these
common genes, representative ones include LIMD1-AS1, which
encodes LIMD1 natural antisense (NAT) long non-coding RNA
(lncRNA), and those encoding the membrane trafﬁcking
regulators RBSN, SACM1L, UNC13B, and ATP11A. We
validated the correlation of LIMD1 with selected genes in both
TCGA and GTEx lung cancer datasets, by one-to-one paired

Frontiers in Oncology | www.frontiersin.org
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FIGURE 5 | LIMD1-associated molecular signature in NSCLC. (A) Proﬁling genes coexpressed with LIMD1 in NSCLC in GEPIA2. Pearson correlation coefﬁcient
values (PCC) >0.5 are shown. (B) Validation of individual genes in association with LIMD1 transcription in GEPIA2. (C) Similar expression patterns of LIMD1 and
LIMD1-AS1 across various cancer versus normal tissues, as analyzed in GEPIA2. Cancer types are labeled on the top of the graphs, with red fonts showing
signiﬁcant upregulation and green fonts showing signiﬁcant downregulation. T, Tumor tissues (Red dots); N, Normal tissues (Green dots).

In agreement with this ﬁnding, neutrophils were reported to
dominate the immune cell composition in NSCLC (49). Further,
LIMD1 signiﬁcantly correlates with tumor-inﬁltrating regulatory
T cells (Treg) and negatively correlates with tumor-inﬁltrating
MDSCs in LUAD, and also signiﬁcantly correlates with tumorinﬁltrating macrophages and B cells in LUSC (Figure 6B). These
ﬁndings imply that these TILs may play plausible and unique

Frontiers in Oncology | www.frontiersin.org

roles in regulating anti-tumor immunity in LUAD and LUSC,
although currently, they are not ideal pharmacological targets.
We further show that Limd1 gene promoter methylation
levels signiﬁcantly correlate with the frequencies of activated
tumor-inﬁltrating CD4+ and CD8+ T cells and B cells (R<-0.30
or R>0.30 and p<0.05), with greater correlation coefﬁcients in
LUAD compared with LUSC (Figure 6C).
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FIGURE 6 | LIMD1 correlates with immune inﬁltration in NSCLC. (A, B) LIMD1 expression signiﬁcantly correlates with a subgroup of immune inﬁltrating lymphocytes
in LUAD and LUSC. (C) Methylation of the Limd1 gene promoter signiﬁcantly correlates with immune inﬁltration. (D) LIMD1 expression signiﬁcantly correlates with a
subset of immune regulatory molecules in LUAD. (A, B) are the results from TIMER2, and (C, D) from TISIDB.
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with TCGA, EGA, and GEO datasets. We found that the
abundance of LIMD1 is signiﬁcantly associated with overall
survival (OS) of HPV-positive HNSC, KICH, KIRC, LGG,
LUAD, and READ, and representative results from TIMER2
are shown in Figure 7A.
Regarding the prognostic implications of LIMD1 in NSCLC
patients, similar results were obtained from TIMER2, TISIDB,
DriverDBv3, and KMPlot portals showing that the LIMD1
expression levels positively correlate with the overall survival
(OS) of LUAD but not that of LUSC patients (HR=0.67,
p=0.0015 in KMPlot; p=0.00656 in TISIDB; HR=0.829,
p=0.00761 in TIMER2; and HR=0.616, p=0.00328 in
DriverDBv3 for LUAD. HR=0.85, p=0.33 in KMPlot; p=0.713
in TISIDB; HR=1.09, p=0.195 in TIMER2; and HR=1.42,
p=0.0109 in DriverDBv3 for LUSC) (Figure 7B; Results from
DriverDBv3 not shown). These results indicate that LIMD1 can
serve as a promising prognostic biomarker for LUAD (but not
for LUSC). In line with our ﬁndings, LIMD1 was shown as a
prognostic indicator for NSCLC, and its loss signiﬁcantly

We next evaluated LIMD1 in correlation with immune
regulatory molecules (suppressors and stimulators) at their
expression levels. Within the cutoff values of R<-0.30 or
R>0.30 and p<0.05, we identiﬁed LIMD1 mRNA abundance
signiﬁcantly correlates with IL6R and TNFSF15, and negatively
correlates with TNFSF4 and TNFSF18. LIMD1 also negatively
correlates with the MHC molecular TAP1 (Figure 6D).
However, no correlation between LIMD1 and any of these
molecules in LUSC within the criteria (not shown).

High LIMD1 Expression Levels Favor the
Prognosis of LUAD but Not LUSC Patients
Regarding the clinical outcomes of LIMD1 deregulation in
NSCLC, we assessed the prognosis values of LIMD1
deregulation in various cancers. To this end, the relation
between LIMD1 expression levels and the overall survival (OS)
rates of cancer patients was analyzed in different portals,
including TIMER2, TISIDB, GEPIA2, and DriverDB portals
with TCGA dataset, and Kaplan Meier plotter (KMPlot) portal

A

B

FIGURE 7 | LIMD1 correlates with the overall survival of certain cancers. (A) LIMD1 expression level correlates with the overall survival (OS) of certain cancer
patients (200 months). (B) LIMD1 expression level signiﬁcantly correlates with OS of LUAD patients, but not with LUSC patients. (A) are results from TIMER2, and
(B) from different portals showing the consistency. For KMPlot, the settings were: only JetSet best probe set, excluding outlier arrays, and univariate.
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favoring the prognosis of LUAD, but not LUSC (Figure 7).
7) Mechanistically, our analysis indicates that LIMD1 expression
level correlates with the deregulation of various cellular
functions, including cell proliferation and survival, oxidative
stress, and cell cycle progress, which are mediated by EGFR,
KRAS, PI3K, and Keap1, in both LUAD and LUSC, and
speciﬁcally correlates with the deregulation of the pathways
mediated by p53 and CDKN2A in LUAD (Figure 8).
Overexpression of LIMD1 was shown to be a hallmark of
ABC type of DLBC (55). Our GEO high throughput proﬁling has
revealed that LIMD1 is associated with IRF4 expression in B-cell
lymphomas, including EBV-associated lymphomas and DLBC
(12). The human LIMD1 promoter and the predominant
transcription start sites (TSS) were characterized (8), and Pu.1
was reported to be the major transcription factor that activates
LIMD1 transcription (56). Of great interest, we identiﬁed at least
one conserved functional NFkB-binding site and an ETS/ISREconsensus element (EICE) upstream of the TSS; the latter can
bind to the oncogenic transcription factor IRF4 (11).
Correspondingly, we showed that LIMD1 is transcriptionally
regulated by both IRF4 and NFkB downstream of LMP1
signaling in EBV-transformed cells (11).
Considering its downregulation in NSCLC, LIMD1 was
shown to be regulated by HIF1a under hypoxia in a negative
feedback loop (4). Interestingly, our results suggest that p53 may
transcriptionally activate LIMD1 in LUAD (Figure 4G), in
addition to a partial contribution from its promoter
methylation (Figures 2F-I) and from the mutation of speciﬁc
genes (Supplementary Figure 5). Of speciﬁc interest, our results
show that LIMD1-AS1, a NAT lncRNA of LIMD1, perfectly
correlates with LIMD1 at the transcriptional level in various
cancers. In general, NAT lncRNAs are able to regulate expression
of their sense protein-coding partner genes in cis (so called cisNATs) (57–62). In line with our ﬁndings, LIMD1-AS1 was
recently shown to stabilize LIMD1 mRNA in lung cancer (41).
Apart from these epigenetic mechanisms, it is worthy of further
investigation of potential transcriptional regulation mediated by
other transcription factors, which may be lung cancer speciﬁc. In
fact, LIMD1 is transcriptionally deregulated in response to
various drug treatments that modulate signaling pathways
mediated by various receptors, kinases, transcription factors,
and others (Supplementary Table 5).
LIMD1 has both cytoplasmic and nuclear roles, due to its
ability to shuttle between the cytoplasmic and nuclear
compartments. It is known to be engaged in the regulation of
HIF1a, Wnt and Hippo, and cytoskeletal pathways in the
cytoplasmic compartment (5, 13, 14, 50), and positively
regulates microRNA (miRNA)-mediated gene silencing (6). As
a multifunctional protein, it also inhibits E2F-mediated gene
transcription in the nucleus (2). Of importance, our metaanalysis implies novel functions and mechanisms of LIMD1 in
NSCLC, highlighted by the ﬁndings that it signiﬁcantly correlates
with speciﬁc immune inﬁltrating lymphocytes, especially with
neutrophils, in both LUAD and LUSC (Figure 6), and with a
panel of factors involved in membrane trafﬁcking (Figure 5).
However, LIMD1 deregulation is only signiﬁcantly associated

worsened 5-year OV of the patients (4). These ﬁndings underline
the correlation between LIMD1 expression and clinical outcomes
in LUAD patients.

Possible Mechanism Underneath TumorSuppressing Function of LIMD1 in NSCLC
To explore the potential mechanisms responsible for LIMD1mediated tumor suppression, we ﬁrst analyzed genome-wide
LIMD1 interaction network in STRING, BioGRID, and
GeneMANIA. Results show that a spectrum of proteins
physically interact with LIMD1 in humans, as discovered in
both high and low throughput proﬁling assays (66 in
BioGRID) (Figures 8A, B), in addition to RHOBTB3 (13),
VHL (4, 5), TRAF6 (11, 50), SQSTM1 (p62) (51, 52), LATS1/
2 (14, 53, 54), and FLNA/B/C (1), which are known to
functionally or physically interact with LIMD1 (Supplementary
Table 4). These LIMD1 interactors are involved in broad
biological processes.
Finally, we analyzed the possible pathways with the
involvement of LIMD1 in KEGG and Uniport (Supplementary
Figure 6), and those associated with LIMD1 downregulation in
NSCLC in cBioportal (Figures 8C, D). Results show that LIMD1
deregulation has a remarkable association with EGFR-RTKKRAS and PI3K/mTOR pathways that regulate cell
proliferation and survival, with Keap1-NRF2 pathway that
serves as the master antioxidant defense mechanism, and with
SOX2/p63 that inhibit NOTCH signaling (Figure 8C), in both
LUAD and LUSC. More importantly, in support of its
correlation with the survival of LUAD patients (Figure 7),
LIMD1 downregulation greatly correlates with the deregulation
of p53-mediated cell proliferation and survival, and with the
deregulation of CDKN2A-Rb-mediated cell cycle progress, in
LUAD but not in LUSC (Figure 8D).

DISCUSSION
In this algorithm-based study, we show that: 1) LIMD1 is
signiﬁcantly deregulated in several malignancies, including its
downregulation in NSCLC (Figure 2); 2) LIMD1 promoter
methylation, but not its mutations that occur at low rates in
NSCLC, makes a signiﬁcant contribution to its downregulation
in NSCLC (Figure 2; Figure 4); 3) Downregulation of LIMD1
transcription occurs at early stages of NSCLC, and smoke status,
ages, gender, and races of the patients do not correlate with its
downregulation (Figure 3); 4) LIMD1 perfectly correlates with
LIMD1-AS1 at the mRNA expression level in various cancers,
including NSCLC, and also signiﬁcantly correlates with a panel
of membrane trafﬁcking regulators in NSCLC (Figure 5).
5) LIMD1 signiﬁcantly correlates (most positively) with several
subtypes of TILs, with neutrophils being the majority of TILs, in
both LUAD and LUSC. Correspondingly, LIMD1 expression
correlates (positively or negatively) with a subgroup of
immunomodulators (Figure 6). 6) More importantly, we
found that LIMD1 deregulation is signiﬁcantly associated with
the prognosis of several malignancies, with its high levels
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A

B

C

D

FIGURE 8 | Genome-wide interaction and pathway association of LIMD1 in NSCLC. (A) Known LIMD1 protein physical interaction network, as analyzed in STRING
databases. Co-expression, textmining, neighborhood, and gene fusion were excluded in the settings. Green line: from curated databases; Pink line: Experimentally
validated; Purple line: Proteins with homology. (B) Physical interactors of LIMD1 protein as identiﬁed in BioGRID with various databases from both high and low
throughput assays. Blue: Associated protein from the same organism; Yellow: Associated protein from a different organism (PPP2R1A and PPP2R3A are from
mouse, and GAG-POL from HIV). (C) The pathways that are deregulated in correlation with LIMD1 in both LUAD and LUSC. (D) The unique pathways that are
deregulated in correlation with LIMD1 in LUAD. The deregulation of individual genes is shown in red. The more frequently a given gene is deregulated, the deeper red
is shown.
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underneath the interaction of LIMD1 with NSCLC, for example,
site-speciﬁc phosphorylation at S233, S272, and S277 of LIMD1
and LIMD1-mediated immune inﬁltration in this setting. These
underlying molecular mechanisms of LIMD1-mediated antioncogenesis in NSCLC merit further experimental validation
and elaboration, which will be our priority in the
following pursuits.

with the prognosis of LUAD but not that of LUSC, implying that
other LIMD1-mediated functions contribute to the prognosis of
NSCLC patients. In fact, the LIMD1 expression levels correlate
with the mutation of key tumor suppressors and promoters
(Figure 4G), and with the deregulation of p53 and CDKN2A
pathways (Figure 8D), only in LUAD, not in LUSC, suggesting
that the deregulation of these pathways speciﬁcally favors
LUAD development.
LIMD1 is heavily phosphorylated (PhosphoSitePlus.org), such as
Y21, Y179, S233, S272, S277, S316, S421, S424, Y527 in humans,
with a few sites experimentally validated that render its different
functions (33, 63). Cell-cycle-dependent phosphorylation of LIMD1
may play a role in breast cancer (33). Interestingly, our results
suggest that phosphorylation of S233 of LIMD1 may be associated
with its function in lung cancer (Figure 2E). Indeed, different
chemotherapeutic treatments result in distinct site-speciﬁc LIMD1
phosphorylation, with the highest frequencies at the sites S272 and
S277 (Supplementary Figure 7), with experimental validation in
lung cancer cell lines showing that phosphorylation of these sites in
mitosis is required for mitotic progression and LIMD1 tumorsuppressing activity (63). In addition to site-speciﬁc
phosphorylation, other post-translational modiﬁcations (PTMs),
including ubiquitination and acetylation, were identiﬁed for
LIMD1 by high throughput assays, as shown in ProteomicsDB
and PhosphoSitePlus portals (not shown).
Besides these mechanisms, disclosing other potential
unknown mechanisms underneath context-dependent LIMD1
deregulation and its promo-oncogenic and anti-oncogenic roles
in cancers will be our future priority of study. Importantly, our
recently published ﬁndings have shown that LIMD1 is associated
with DNA damage response and protects B lymphoma cells from
DNA damage-induced cell death, which represents a novel
mechanism accounting for its oncogenic properties in this
setting (11, 64). Of great interest, we have also generated a
pool of preliminary data showing that LIMD1 is tightly
associated with the autophagy program, which counteracts
tumorigenesis at early stages while promotes survival and
progression of already established cancers, including lung
cancer (65–71). In support of its role in autophagy, our results
in this study show that LIMD1 correlates with a pool of
membrane trafﬁcking regulators (Figure 5).
In summary, this meta-analysis indicates that LIMD1, as a
tumor suppressor in lung cancer, is signiﬁcantly downregulated
in NSCLC, and could serve as a prognosis marker for LUAD but
not for LUSC. This study represents a breath of cancer patient
sample databases, and discloses various potential mechanisms
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